首页> Alzheimer's & dementia (New York, N. Y.)> Multiple-dose ponezumab for mild-to-moderate Alzheimer's disease: Safety and efficacy.

Multiple-dose ponezumab for mild-to-moderate Alzheimer's disease: Safety and efficacy.

导出 LinkOut

翻译打印收藏纠错

第一作者： Jaren W,Landen

第一单位： Pfizer Inc., Groton, CT, USA.

作者： Jaren W,Landen ^[1] ; Sharon,Cohen ^[2] ; Clare B,Billing ^[1] ; Carol,Cronenberger ^[1] ; Scot,Styren ^[1] ; Aaron H,Burstein ^[1] ; Catherine,Sattler ^[1] ; Jae-Hong,Lee ^[3] ; Clifford R,Jack ^[4] ; Kejal,Kantarci ^[4] ; Pamela F,Schwartz ^[1] ; William T,Duggan ^[1] ; Qinying,Zhao ^[1] ; Ken,Sprenger ^[1] ; Martin M,Bednar ^[5] ; Brendon,Binneman ^[5]

作者单位： Pfizer Inc., Groton, CT, USA. ^[1] Toronto Memory Program, Toronto, Ontario, Canada. ^[2] Department of Neurology, Asan Medical Center, Seoul, Korea. ^[3] Department of Radiology, Mayo Clinic, Rochester, MN, USA. ^[4] Pfizer Inc., Cambridge, MA, USA. ^[5]

关键词 Alzheimer's disease Amyloid β Biomarkers Cerebrospinal fluid Immunotherapy Monoclonal antibody Pharmacodynamics Pharmacokinetics Phase-II study Ponezumab

DOI 10.1016/j.trci.2017.04.003

PMID 29067341

发布时间 2024-07-18

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览6

Alzheimer's & dementia (New York, N. Y.)

2017年3卷3期

339-347页

相似文献

中文期刊
外文期刊
学位论文
会议论文

浏览6

点击下载本期目录封面

Alzheimer's & dementia (New York, N. Y.)

2017年3卷3期

339-347页

检索历史清除

Multiple-dose ponezumab for mild-to-moderate Alzheimer's disease: Safety and efficacy.

Alzheimer's & dementia (New York, N. Y.)

相似文献

同项目论文

Alzheimer's & dementia (New York, N. Y.)

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Multiple-dose ponezumab for mild-to-moderate Alzheimer's disease: Safety and efficacy.

Alzheimer's & dementia (New York, N. Y.)

相似文献

同项目论文

Alzheimer's & dementia (New York, N. Y.)

相关期刊

检索历史清除